Pinney principals spotlight abuse-deterrent opioids with FDA
The FDA holds regular public meetings, many of which are simulcast on the web. Its Oct. 31 webcast on the Development and Regulation of Opioid Analgesics with Abuse-Deterrent (AD) Properties Meeting served as the platform for Dr. Jack Henningfield, Pinney’s vice president of research, health policy and abuse liability; and Dr. Edward Cone, principal scientist, drug delivery and abuse deterrent drug products.
Each presented at the event on issues concerning the formulation and evaluation of opioid drug products with abuse-deterrent properties.
"We have seen the success of abuse-deterrent products with lower rates of abuse and overdose than expected for comparable non-AD opioids,” Henningfield said. “However, opioid abuse, overdose and other adverse public health outcomes remain a major public health problem.”
Henningfield added that industry stakeholders must continue to afford individuals with substance use disorders better access to treatment. Cone agreed that while the FDA has done much to reduce abuse and addiction, plenty of work remains, particularly regarding abuse-deterrent or tamper-proof formulations of opioids.
Pinney Associates provides its pharmaceutical and health care clients with services to minimize risk and maximize product values, with expertise in abuse-deterrent drug evaluation.
Organizations in this story
PinneyAssociates 4800 Montgomery Ln Bethesda, MD 20814